Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study
Atrial fibrillation (AF) is a progressive disease, and early recognition and management may reflect an important strategy to reduce its disease burden. In this study, we evaluated plasma levels of three biomarkers - N-terminal pro-brain natriuretic peptide (NTproBNP), Troponin-T, and growth differen...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | International Journal of Cardiology: Heart & Vasculature |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906722000367 |
| _version_ | 1819157043775275008 |
|---|---|
| author | L.M.G. Meems V. Artola Arita M. Velt E.A.M.P. Dudink H.J.G.M. Crijns I.C. Van Gelder M. Rienstra |
| author_facet | L.M.G. Meems V. Artola Arita M. Velt E.A.M.P. Dudink H.J.G.M. Crijns I.C. Van Gelder M. Rienstra |
| author_sort | L.M.G. Meems |
| collection | DOAJ |
| description | Atrial fibrillation (AF) is a progressive disease, and early recognition and management may reflect an important strategy to reduce its disease burden. In this study, we evaluated plasma levels of three biomarkers - N-terminal pro-brain natriuretic peptide (NTproBNP), Troponin-T, and growth differentiation factor-15 (GDF-15) - in patients with paroxysmal AF (pAF) (≤7 days of continuous AF, n = 323) and persistent AF ((AF duration > 7 days and < 1 year, n = 84) using patients from AF RISK study (NCT01510210). In this AF-RISK sub-study, patients with persistent AF experienced more symptoms (higher European Heart Rhythm Association class (p < 0.001)), had a higher comorbidity burden (p < 0.001), and had more unfavorable echocardiographic parameters (p < 0.001). All three biomarker levels were significantly higher in patients with persistent AF as compared to those with pAF (p < 0.001). Multivariate linear regression analyses showed that age (beta-coefficient for NTproBNP: 0.21; GDF-15: 0.41; Troponin-T: 0.23) and CHA2DS2-VASc (beta-coefficient for NTproBNP: 0.20; GDF-15: 0.25; Troponin-T: 0.27) were determinants of all three biomarkers, and that persistent AF determined NTproBNP (beta-coefficient: 0.34), but not Troponin-T and GDF-15. More detailed analysis of CHA2DS2-VASc score showed that for all three biomarkers age, coronary artery disease and heart failure were determinants of plasma biomarkers levels, whereas sex determined NTproBNP and Troponin T, and hypertension determined NTproBNP and GDF15. Overall, this study therefore suggests that in AF, Troponin T and GDF15, and especially NTproBNP could be used to detect those patients with more persistent form of AF that may warrant more aggressive treatment of AF and concomitant comorbidities. Future studies, however, are essential to evaluate if more aggressive AF treatment and risk factor management will reduce disease progression and holds a novel therapeutic intervention to reduce the burden of AF. |
| first_indexed | 2024-12-22T16:02:30Z |
| format | Article |
| id | doaj.art-455720cfc5d941628eeffdbec14f339e |
| institution | Directory Open Access Journal |
| issn | 2352-9067 |
| language | English |
| last_indexed | 2024-12-22T16:02:30Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Cardiology: Heart & Vasculature |
| spelling | doaj.art-455720cfc5d941628eeffdbec14f339e2022-12-21T18:20:40ZengElsevierInternational Journal of Cardiology: Heart & Vasculature2352-90672022-04-0139100987Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK studyL.M.G. Meems0V. Artola Arita1M. Velt2E.A.M.P. Dudink3H.J.G.M. Crijns4I.C. Van Gelder5M. Rienstra6Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsMaastricht University Medical Center+ and Cardiovascular Research Institute Maastricht, Maastricht, the NetherlandsMaastricht University Medical Center+ and Cardiovascular Research Institute Maastricht, Maastricht, the NetherlandsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Corresponding author at: Department of Cardiology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands.Atrial fibrillation (AF) is a progressive disease, and early recognition and management may reflect an important strategy to reduce its disease burden. In this study, we evaluated plasma levels of three biomarkers - N-terminal pro-brain natriuretic peptide (NTproBNP), Troponin-T, and growth differentiation factor-15 (GDF-15) - in patients with paroxysmal AF (pAF) (≤7 days of continuous AF, n = 323) and persistent AF ((AF duration > 7 days and < 1 year, n = 84) using patients from AF RISK study (NCT01510210). In this AF-RISK sub-study, patients with persistent AF experienced more symptoms (higher European Heart Rhythm Association class (p < 0.001)), had a higher comorbidity burden (p < 0.001), and had more unfavorable echocardiographic parameters (p < 0.001). All three biomarker levels were significantly higher in patients with persistent AF as compared to those with pAF (p < 0.001). Multivariate linear regression analyses showed that age (beta-coefficient for NTproBNP: 0.21; GDF-15: 0.41; Troponin-T: 0.23) and CHA2DS2-VASc (beta-coefficient for NTproBNP: 0.20; GDF-15: 0.25; Troponin-T: 0.27) were determinants of all three biomarkers, and that persistent AF determined NTproBNP (beta-coefficient: 0.34), but not Troponin-T and GDF-15. More detailed analysis of CHA2DS2-VASc score showed that for all three biomarkers age, coronary artery disease and heart failure were determinants of plasma biomarkers levels, whereas sex determined NTproBNP and Troponin T, and hypertension determined NTproBNP and GDF15. Overall, this study therefore suggests that in AF, Troponin T and GDF15, and especially NTproBNP could be used to detect those patients with more persistent form of AF that may warrant more aggressive treatment of AF and concomitant comorbidities. Future studies, however, are essential to evaluate if more aggressive AF treatment and risk factor management will reduce disease progression and holds a novel therapeutic intervention to reduce the burden of AF.http://www.sciencedirect.com/science/article/pii/S2352906722000367Atrial fibrillationBiomarkersNTproBNPGrowth-differentiation factor 15Troponin T |
| spellingShingle | L.M.G. Meems V. Artola Arita M. Velt E.A.M.P. Dudink H.J.G.M. Crijns I.C. Van Gelder M. Rienstra Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study International Journal of Cardiology: Heart & Vasculature Atrial fibrillation Biomarkers NTproBNP Growth-differentiation factor 15 Troponin T |
| title | Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study |
| title_full | Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study |
| title_fullStr | Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study |
| title_full_unstemmed | Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study |
| title_short | Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study |
| title_sort | increased plasma levels of nt probnp troponin t and gdf 15 are driven by persistent af and associated comorbidities data from the af risk study |
| topic | Atrial fibrillation Biomarkers NTproBNP Growth-differentiation factor 15 Troponin T |
| url | http://www.sciencedirect.com/science/article/pii/S2352906722000367 |
| work_keys_str_mv | AT lmgmeems increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT vartolaarita increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT mvelt increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT eampdudink increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT hjgmcrijns increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT icvangelder increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy AT mrienstra increasedplasmalevelsofntprobnptroponintandgdf15aredrivenbypersistentafandassociatedcomorbiditiesdatafromtheafriskstudy |